 All participants will be asked to take the tablets of TAK-659 at the same time each day throughout the study. Participants will also receive intravenous infusion of nivolumab within 30 minutes after the TAK-650 dose once every 2 weeks. This multi-center trial will be conducted globally. The overall time to receive treatment in this study is approximately 12 months. Participants will be assessed for disease response and PD during the PFS follow-up of 6 months for participants who discontinue due to reasons other than PD and OS follow-up of 12 months from the last dose of study drug. 